Literature DB >> 27864430

APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death.

Yulong Fu1, Jun-Yi Zhu1, Adam Richman1, Yi Zhang1,2, Xuefang Xie2, Jharna R Das2,3,4, Jinliang Li2,4, Patricio E Ray2,3,4, Zhe Han5,4.   

Abstract

People of African ancestry carrying certain APOL1 mutant alleles are at elevated risk of developing renal diseases. However, the mechanisms underlying APOL1-associated renal diseases are unknown. Because the APOL1 gene is unique to humans and some primates, new animal models are needed to understand the function of APOL1 in vivo We generated transgenic Drosophila fly lines expressing the human APOL1 wild type allele (G0) or the predominant APOL1 risk allele (G1) in different tissues. Ubiquitous expression of APOL1 G0 or G1 in Drosophila induced lethal phenotypes, and G1 was more toxic than was G0. Selective expression of the APOL1 G0 or G1 transgene in nephrocytes, fly cells homologous to mammalian podocytes, induced increased endocytic activity and accumulation of hemolymph proteins, dextran particles, and silver nitrate. As transgenic flies with either allele aged, nephrocyte function declined, cell size increased, and nephrocytes died prematurely. Compared with G0-expressing cells, however, G1-expressing cells showed more dramatic phenotypes, resembling those observed in cultured mammalian podocytes overexpressing APOL1-G1. Expressing the G0 or G1 APOL1 transgene in nephrocytes also impaired the acidification of organelles. We conclude that expression of an APOL1 transgene initially enhances nephrocyte function, causing hypertrophy and subsequent cell death. This new Drosophila model uncovers a novel mechanism by which upregulated expression of APOL1-G1 could precipitate renal disease in humans. Furthermore, this model may facilitate the identification of APOL1-interacting molecules that could serve as new drug targets to treat APOL1-associated renal diseases.
Copyright © 2017 by the American Society of Nephrology.

Entities:  

Keywords:  cell biology and structure; cell survival; chronic kidney disease; genetic renal disease

Mesh:

Substances:

Year:  2016        PMID: 27864430      PMCID: PMC5373456          DOI: 10.1681/ASN.2016050550

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  55 in total

1.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

Review 2.  The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.

Authors:  Barry I Freedman; Jeffrey B Kopp; Carl D Langefeld; Giulio Genovese; David J Friedman; George W Nelson; Cheryl A Winkler; Donald W Bowden; Martin R Pollak
Journal:  J Am Soc Nephrol       Date:  2010-08-05       Impact factor: 10.121

3.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

4.  The basic domain of HIV-tat transactivating protein is essential for its targeting to lipid rafts and regulating fibroblast growth factor-2 signaling in podocytes isolated from children with HIV-1-associated nephropathy.

Authors:  Xuefang Xie; Anamaris M Colberg-Poley; Jharna R Das; Jinliang Li; Aiping Zhang; Pingtao Tang; Marina Jerebtsova; J Silvio Gutkind; Patricio E Ray
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

5.  ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling.

Authors:  Heon Yung Gee; Pawaree Saisawat; Shazia Ashraf; Toby W Hurd; Virginia Vega-Warner; Humphrey Fang; Bodo B Beck; Olivier Gribouval; Weibin Zhou; Katrina A Diaz; Sivakumar Natarajan; Roger C Wiggins; Svjetlana Lovric; Gil Chernin; Dominik S Schoeb; Bugsu Ovunc; Yaacov Frishberg; Neveen A Soliman; Hanan M Fathy; Heike Goebel; Julia Hoefele; Lutz T Weber; Jeffrey W Innis; Christian Faul; Zhe Han; Joseph Washburn; Corinne Antignac; Shawn Levy; Edgar A Otto; Friedhelm Hildebrandt
Journal:  J Clin Invest       Date:  2013-07-08       Impact factor: 14.808

6.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Authors:  Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

Review 7.  The evolving science of apolipoprotein-L1 and kidney disease.

Authors:  Teresa K Chen; Michelle M Estrella; Rulan S Parekh
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-05       Impact factor: 2.894

8.  Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death.

Authors:  Kayo Okamura; Patrick Dummer; Jeffrey Kopp; Liru Qiu; Moshe Levi; Sarah Faubel; Judith Blaine
Journal:  PLoS One       Date:  2013-01-28       Impact factor: 3.240

9.  Targeted gene expression as a means of altering cell fates and generating dominant phenotypes.

Authors:  A H Brand; N Perrimon
Journal:  Development       Date:  1993-06       Impact factor: 6.868

10.  The insect nephrocyte is a podocyte-like cell with a filtration slit diaphragm.

Authors:  Helen Weavers; Silvia Prieto-Sánchez; Ferdinand Grawe; Amparo Garcia-López; Ruben Artero; Michaela Wilsch-Bräuninger; Mar Ruiz-Gómez; Helen Skaer; Barry Denholm
Journal:  Nature       Date:  2008-10-29       Impact factor: 49.962

View more
  38 in total

1.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

Review 2.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

3.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

Review 4.  Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.

Authors:  Kimberly J Reidy; Rebecca Hjorten; Rulan S Parekh
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

5.  ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

Authors:  John F O'Toole; William Schilling; Diana Kunze; Sethu M Madhavan; Martha Konieczkowski; Yaping Gu; Liping Luo; Zhenzhen Wu; Leslie A Bruggeman; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-11-27       Impact factor: 10.121

6.  Intracellular APOL1 Risk Variants Cause Cytotoxicity Accompanied by Energy Depletion.

Authors:  Daniel Granado; Daria Müller; Vanessa Krausel; Etty Kruzel-Davila; Christian Schuberth; Melanie Eschborn; Roland Wedlich-Söldner; Karl Skorecki; Hermann Pavenstädt; Ulf Michgehl; Thomas Weide
Journal:  J Am Soc Nephrol       Date:  2017-07-10       Impact factor: 10.121

7.  Identifying the Intracellular Function of APOL1.

Authors:  Leslie A Bruggeman; John F O'Toole; John R Sedor
Journal:  J Am Soc Nephrol       Date:  2017-02-14       Impact factor: 10.121

8.  Chronic kidney disease: Mechanisms of APOL1-associated renal disease.

Authors:  Ellen F Carney
Journal:  Nat Rev Nephrol       Date:  2016-12-05       Impact factor: 28.314

9.  APOL1 variants change C-terminal conformational dynamics and binding to SNARE protein VAMP8.

Authors:  Sethu M Madhavan; John F O'Toole; Martha Konieczkowski; Laura Barisoni; David B Thomas; Santhi Ganesan; Leslie A Bruggeman; Matthias Buck; John R Sedor
Journal:  JCI Insight       Date:  2017-07-20

10.  Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Charles R Swanepoel; Mohamed G Atta; Vivette D D'Agati; Michelle M Estrella; Agnes B Fogo; Saraladevi Naicker; Frank A Post; Nicola Wearne; Cheryl A Winkler; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christina M Wyatt
Journal:  Kidney Int       Date:  2018-02-03       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.